GBS GLUCOSE BIOSENSOR SYS

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

Company to Host Conference Call & Webcast at 4:30 p.m. ET

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET.

Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results

Conference Call & Webcast
Date:Wednesday, August 31, 2022
Time:4:30 p.m. ET
Conference Call Details:Toll-Free: 877-407-3982

International: 201-493-6780

Conference ID: 13731215
 
The conference call will be webcast live from the Company’s website and will be available via the following links:

 
Webcast:



  
The webcast should be accessed 15 minutes prior to the conference call start time.

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About GBS Inc.:

GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit .        

Company Contact:

Alex Arzeno – Vice President of IR & Communications

GBS, Inc.

Investor Contact:

Tim McCarthy – Managing Director

LifeSci Advisors, LLC



EN
29/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint D...

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical...

 PRESS RELEASE

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results a...

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements 20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent,...

 PRESS RELEASE

Intelligent Bio Solutions Drives Global Growth Through Multilingual Di...

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabi...

 PRESS RELEASE

Intelligent Bio Solutions Expands Global Reach with Latin American Spa...

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by 2030 Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” o...

 PRESS RELEASE

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic...

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company’s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch